Avenue Therapeutics (ATXI) Misses Q2 EPS by 39c

Avenue Therapeutics (NASDAQ: ATXI) reported Q2 EPS of ($0.52), $0.39 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules